Veröffentlichungen
Roll P, Palanichamy A, Kneitz C, Dörner T, Tony HP: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 54(8):2377-2386 (2006)
Roll P, Dörner T, Tony HP: Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58(6):1566-1575 (2008)
Palanichamy A, Roll P, Theiss R, Dörner T, Tony HP: Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. Arthritis Rheum 58(12):3665-3674 (2008)
Feuchtenberger M, Müller S, Roll P, Waschbisch A, Schäfer A, Kneizt C, Wiendl H, Tony HP: Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. The Open Rheumatology Journal 2:81-88 (2008)
Muhammad K, Roll P, Einsele H, Tony HP: Delayed Acquisition of Somatic Hypermutations in Repopulated IgD+CD27+ Memory B Cell Receptors After Rituximab Treatment. Arthritis Rheum 60(8):2284-2293 (2008)
Feuchtenberger M, Kneitz C, Roll P, Kleinert S, Tony HP: Sustained remission after combination therapy with rituximab and etanercept in two patients with rheumatoid arthritis after TNF failure: case report. The Open Rheumatology Journal 3:9-13 (2009)
Roll P, Muhammad K, Schumann M, Kleinert S, Einsele H, Dörner T, Tony HP: In vivo effects of the anti-interleukin 6 inhibitor tocilizumab on the B cell compartment. Arthritis Rheum 63(5):1255-1264 (2011)
Muhammad K, Roll P, Seibold T, Einsele H, Dörner T, Tony HP: Impact of IL-6 receptor inhibition on human memory B cells in vivo: Impaired somatic hypermutation in pre-switch memory B cells and modulation of mutational targeting in memory B cells. Ann Rheum Dis, 70(8):1507-10 (2011)
Feuchtenberger M, Kleinert S, Schwab S, Roll P, Scharbatke EC, Ostermeier E, Voll RE, Schäfer A, Tony HP: Vaccination Survey in Patients with Rheumatoid Arthritis: A Cross Sectional Study. Rheumatol Int 32(6);1533-9 (2011)
Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP: RF positivity has substantial influence on the peripheral memory B cell compartment and its modulation by TNF inhibition. Scand J Rheumatol Scand J Rheumatol 41(3):180-5 (2012)
Roll P, Muhammad K, Schumann M, Kleinert S, Tony HP: RF positivity has substantial influence on the peripheral memory B cell compartment and its modulation by TNF inhibition. Scand J Rheumatol (2011, submitted) Roll P, Ostermeier E, Haubitz M, Lovric S, Unger L, Holle J, Kötter I, Henes JC, Bergner R, Rubbert-Roth A, Specker C, Schulze-Koops H, Müller-Ladner U, Fleck M, Burmester GR, Hiepe F, Heitmann S, Aringer M, Fischer-Betz R, Dörner T, Tony HP: Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID). J Rheumatol 39(11):2135-6 (2012).
Palanichamy A, Muhammad K, Roll P, Kleinert S, Dörner T, Tony HP: Rituximab therapy leads to reduced imprints of receptor revision in immunoglobulin κ and χ light chains. J Rheumatol 39(6):1130-8 (2012)
Kleinert S, Roll P, Baumgaertner C, Himsel A, Müller A, Fleck M, Feuchtenberger M, Jenett M, Tony HP: Renal perfusion in scleroderma patients assessed by microbubble-based contrast-enhanced ultrasound. Open Rheumatol J 6:50-3 (2012)
Roll P, Mahmood Z, Muhammad K, Feuchtenberger M, Dörner T, Tony HP: Long-term repopulation of peripheral B cell subsets after single and repeated rituximab infusions in patinets with rheumatoid arthritis. Clin Exp Rheumatol 33(3):347-353, 2015
Roll P, Dörner T, Tony HP: Reply. J Rheumatol 40(2):203, 2013
Mahmood Z, Muhammad K, Schmalzing M, Roll P, Dörner T, Tony HP: CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Res Ther 14;17-61, 2015
Roll P, Muhammad K, Stuhler G, Grigoleit U, Einsele H, Tony HP: Effect of ATG-F on B-cell reconstitution after hematopoietic stemm cell transplantation. Eur J Haematol 2015 Feb 12.doi:10/1111/ejh 12524
Tony HP*, Roll P*, Mei HE, Blümner E, Straka A, Gnuegge L, Dörner T on behalf of the Refirst study team: Combination of B-cell biomarkers as independent predictors of response in patients with RA treatec with rituximab. Clin Exp Rheumatol 2015;33(6):887-894, these authors contributed equally
Roll P, Rubbert-Roth A, Tony HP: Was kommt nach TNF im klinischen Alltag? Tocilizumab bei rheumatoider Arthritis. Z Rheum 69(7):608-617 (2010)
Roll P, Tony HP: B-Zell gerichtete Therapie bei Autoimmunerkrankungen. Z Rheum 68(3):255-59 (2009)
Roll P, Tony HP: Anti-CD20 Therapie bei rheumatoider Arthritis. Z Rheum 68(5):370-379 (2009)
Roll P, Kleinert S, Tony HP: Differenzialdiagnostik der akuten Monarthritis. MMW Fortschr. Med. 44:44-48 (2007)
Ostermeier E, Roll P, Tony HP: Intrazelluläre Therapieverfahren in der Rheumatologie- JAK Kinasehemmer- schon serienreif? Z Rheumatol 71(6):473-8 (2012)
Roll P, Muhammad K, Schumann M, Kleinert S, Dörner T, Tony HP: Substantial influence of rheumatoid factor positivity on the peripheral memory B cells and its modulation by TNF inhibition in RA. ACR 2011
Roll P, Muhammad K, Schumann M, Kleinert S, Dörner T, Tony HP: In vivo effects of tocilizumab on peripheral B cells in patients with rheumatoid arthritis. ACR 2010, A 745
Roll P, Ostermeier E, Tony HP, Burmester GR, Dörner T und die AID Studiengruppe: Wirksamkeit und Sicherheit von Rituximab in der Behandlung von ANCA- assoziierten Vaskulitiden: Ergebnisse des deutschen AID Registers. DGRh Kongress 2010 Hamburg.
Roll P, Ostermeier E, Tony HP, Burmester GR, Dörner T and the AID study group: Efficacy and safety of rituximab treatment in ANCA-associated vasculitis: results of the german national registry. Ann Rheum Dis 2010;69(Suppl3):233
Roll P, Kneitz C, Dörner T, Tony HP: B-cell subsets as predictors of response in patients with RA treated with rituximab. Arthritis Rheum 56:A1431 (2007)
Roll P, Kneitz C, Palanichamy A, Tony HP: Repeated B cell depletion with rituximab in patients with RA leads to a comparable B cell regeneration pattern after each treatment. Arthritis Rheum 56:A3 (2006)
Roll P, Feuchtenberger M, Kneitz C, Tony HP: B cell depletion with rituximab in patients with RA causes a sustained suppression of CD27+ B cells and is followed by a period of increased levels of naïve B cells in the peripheral blood. Arthritis Rheum 50;9:S567 (2004)
Roll P, Kneitz C, Palanichamy A, Dörner T, Tony HP: Die wiederholte B-Zelldepletion mit dem anti-CD20 Antikörper Rituximab führt zu einem vergleichbaren Regenerationsmuster peripherer B-Zellsubpopulationen. Deutsche Gesellschaft für Rheumatologie, Jahrestagung, Wiesbaden (2006)
Roll P, Kneitz C, Tony HP: Kombinationstherapie von Etanercept mit Rituximab zur Remissionsinduktion bei 2 Patientinnen mit therapierefraktärer rheumatoider Arthritis. Deutsche Gesellschaft für Rheumatologie, Jahrestagung, Wiesbaden (2006)
Roll P, Palanichamy A, Rouziere AS, Dörner T, Kneitz C, Tony HP: B-Zellregeneration nach passagerer B-Zelldepletion mit Rituximab bei Patienten mit Rheumatoider Arthritis: transiente Rezirkulation von Plasmablasten während der Regenerationsphase. Deutsche Gesellschaft für Rheumatologie, Jahrestagung, Dresden 2005
Roll P, Palanichamy A, Rouziere AS, Dörner T, Kneitz C, Tony HP: B cell regeneration after B cell depletion with rituximab in patients with rheumatoid arthritis: transient recirculation of plasmablasts and increased levels of germinal center founder cells in the early regeneration phase. Arthritis Rheum 52;9:S289 (2005)
Tony HP, Roll P, Mei HE, Gnuegge L, Kandenwein J, Blümner E, Hammes A, Dörner T on behalf of the Refirst study team: Impact of rheumatoid factor and anti-CCP antibodies on EULAR response to long-term treatment with RITUXIMAB in patients with rheumatoid arthritis after failing one TNFi (FIRST and ReFIRST). EULAR 2012
Tony HP, Roll P, Mei HE, Gnuegge L, Kobialko M, Dörner T, First Study Team: Value of predictive B-cell markers for EULAR response to Rituximab in patients with rheumatoid arthritis (FIRST). ACR 2011 Chicago November
Muhammad K, Palanichamy A, Roll P, Kleinert S, Dörner T, Tony HP: Reduced imprints of receptor editing at the immunoglobulin k and λ light chain loci during rituximab treatment. ACR 2011.
Tony HP, Roll P, Mei HE, Gnuegge L, Kobialko M, Dörner T, FIRST Study Team: Predictive factors for resonse to rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(Suppl7):292
Muhammad K, Roll P, Kleinert S, Seibold T, Feuchtenberger M, Dörner T, Tony HP: Impaired somatic hypermutation in pre-switch memory B cells and modulation of mutational targeting in memory B cells during tocilizumab treatment in RA patients. ACR 2010:A1411
Muhammad K, Roll P, Palanichamy A, Dörner T, Tony HP: Repopulation of IgD+CD27+ memory B cells after rituximab: delayed acquisition of mutations in single B cell Ig receptors. Arthritis Rheum 58;9: A749 (2008)
Palanichamy A, Theiss R, Roll P, Longo N, Kneitz C, Dorner T, Tony HP: Change in the mutational pattern of the B cell immunoglobulin receptor during the regeneration phase after transient B cell depletion with anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 56:1984 (2006)
Feuchtenberger M, Müller S, Roll P, Schaefer A, Kneitz C, Tony HP: Frequency of regulatory T cells is not affected by transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum 56:A2 (2006)
Kleinert S, Baumgaertner C, Feuchtenberger M, Roll P, Kneitz C, Tony HP, Jenett M: Changes in renal perfusion in patients with systemic sclerosis. Arthritis Rheum 52;9:A (2005)
Roll P, Tony HP: Overlap Syndrome in Klinische Immunologie, Hrsg. Peter/Pichler/Müller-Ladner. Elsevier GmbH Urban& Fischer Verlag, München. Gebundene Ausgabe, 3. Auflage.
Roll P, Tony HP: Systemische Vaskulitiden: Diagnostik und Therapie aus Sicht des Internisten. Kongressheft Deutsche Gesellschaft für Neurologie, 2005
Ostermeier E, Roll P, Tony HP: Januskinase Inhibitoren. Hrsg. U. Müller-Ladner, Unimed Verlag (2015)